Ra­dius rock­ets high­er as Kel­ly Mar­tin boasts of a big PhI­II suc­cess — but the spoils be­long to Menar­i­ni

Ra­dius Health stuck with some fuzzy top-line Phase III re­sults for its oral SERD ther­a­py elaces­trant, but in­vestors saw enough to push a ral­ly that sparked a big surge in its share price.

Ac­cord­ing to re­searchers, the drug hit both pri­ma­ry end­points among ER+/HER2- breast can­cer pa­tients: beat­ing stan­dard of care on pro­gres­sion-free sur­vival in the over­all pop­u­la­tion and PFS with tu­mors har­bor­ing es­tro­gen re­cep­tor 1 mu­ta­tions — a key fac­tor in de­vel­op­ing re­sis­tance. And while some an­a­lysts were left won­der­ing about spe­cif­ic da­ta, most of the crowd seemed hap­py to hear that the drug is now be­ing steered to the FDA.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER